期刊文献+

血清CXCL10在^(131)I治疗Graves病中的测定意义 被引量:1

Significance of Determination of the Changes in Serum Level of CXCL10 in Patients with Graves' Disease After Radioactive Iodine Therapy
下载PDF
导出
摘要 目的:旨在探讨CXCL10的检测在放射性碘治疗Graves病中的临床应用价值。方法:ELISA分别测定初诊的甲亢患者以及甲亢患者131I治愈后的血清CXCL10的水平,并与正常对照组比较,随后作统计分析CXCL10水平与FT3、FT4是否存在一定的相关性。结果:甲亢患者的CXCL10水平显著高于正常对照组,在131I治愈后的血清水平显著下降,降至正常水平;CXCL10水平与FT3、FT4浓度呈正相关。结论:CXCL10水平与甲状腺的功能密切相关,可作为评判甲亢患者131I治疗效果的有价值的指标。 Objective To investigate the significance of determination of the changes in serum level of CXCLIO in the patients with Graves' disease after radioactive iodine (131 I) therapy. Methods Level of serum CXCLIO in the patients with Graves' disease, the cured patients treated with 131I and compared to the normal control group. Serum CXCL10 level was measured by ELISA. The relationship among CXCL10, free triiodothyronine (FT3 ) and free thyroxine (Ft4) ,then made an analysis statistically. Results The level of CXCL10 in patients with Graves' disease expressed significantly higher than that in the normal control (P 〈 0.05 ), meanwhile, CXCL10 in the cured patients decreased slgnifieanfly (P 〈0. 05); and CXCL10 was positively correlated with FT3 and FT4 (P 〈 0.05). Conclusion The level of CXCL10 was correlated with function of thyroid, CXCL10 might be a valuable indicant to evaluate the therapeutic efficay of Graves' disease after 131I treatment.
出处 《放射免疫学杂志》 CAS 2013年第3期304-306,共3页 Journal of Radioimmanology
基金 安徽省高等学校省级自然科学研究项目(KJ2009B217Z)
关键词 r干扰素诱导蛋白(CXCL10 IP-10) 放射性碘 Graves病游离三碘甲状腺原氨酸游离甲状腺素 CXCLIO, radioactive iodine, Graves' disease, FT3, FT4
  • 相关文献

参考文献8

  • 1Liu L, Callahan MK, Huang D, et al. Chemokine receptor CX-CR3 : an unexpected angina[J]. Curr Top Dev Biol, 2005,68:149-181.
  • 2Antonelli A, Rotondi M, Ferrafi SM, et 8.l. Intederon-gamma-in- ducible atpha-ehemokine CXCL10 involvement in Graves' ophthatmopa- thy: modulation by peroxisome proiiferator-activatod receptor-gamma ago- nlsts[Jl. J Clin Endocrinol Metab, 2006,91(2) :614-620.
  • 3Garcia-L6pez MA, Sancho D, Sgnchez-Madrid F, et 8-l. Thyro- eytes from autoimmune thyroid disorders produce the ehemokines IP-10 and Mig and attract CXCR3 lymphoeytes[ J. J Clin Endocfinol Metab, 2001,86(10) :5008-5016.
  • 4Leite AC, Pedro AB, Romatdini JH. Irdluenee of methirramole and radioactive iodine treatment in the serum levels of the ehemokine CXCL10 in hyperthyroid patients with Graves' disease[ J ]. Horm Metab Res ,2011, 43(3) :194-199.
  • 5Borgogni E, Sarchielli E, Sottili hi, et al. Elocalcitol inhibits in- flammatory responses in hum,m thyroid cells and T cells[ J]. Endocrinol, 2008,149 (7) :3626-3634.
  • 6Rotondi M, Chiovato L. The chemokine system as a therapeutic target in autoimmune thyroid diseases: a focus on the interfemn-/induc- ible ehemokines and their receptor E J 1. Curt Pharm Des, 2011,17 (29) : 3202-3216.
  • 7Crescio]i C, Cosmi L, Borgogni E, et al. Methimsyole inhibits CXC chemokine llgand 10 secretion in human thyrecytes [ J]. J Endocri- nol,2007,195 ( 1 ) : 145-155.
  • 8Liu C, Papewalis C, Domberg J, et al. Chemokines and autoim- mune thyroid diseases[ J ]. Horm Metab Res,2008,40(6) :361-368.

同被引文献8

  • 1Orsini F, Traino AC, Grosso M, et al. Personalization of radioiodine treatment for Graves' disease: a prospective, randomized study with a novel method for calculating the optimal ^131I-iodide activity based on target reduction of thyroid mass [J]. Q J Nucl Med Mol Imaging, 2012, 56(6): 496-502.
  • 2Santulli-Marotto S, Fisher J, Petley T, et al. Surrogate antibodies that specifically bind and neutralize CCL17 but not CCL22 [J]. Monoclon Antib Immunodiagn Immunother, 2013, 32(3): 162-171.
  • 3Lewis A, Atkinson B, Bell P, et al. Outcome of ^131I therapy in hyper- thyroidism using a 550MBq fixed dose regimen [J]. Ulster Med J, 2013, 82(2): 85-88.
  • 4Mysliwiec J, Palyga I, Kosciuszko M, et al. Circulating CXCL9 and CXCL10 as markers of activity of Graves' orbitopathy during treat- ment with corticosteroids and teleradiotherapy [J]. Horm Metab Res, 2012, 44(13): 957-961.
  • 5Ahmadi Z, Arababadi MK, Hassanshahi G. CXCL10 activities, bio- logical structure, and source along with its significant role played in pathophysiology of type I diabetes mellitus [J]. Inflammation, 2013, 36(2): 364-371.
  • 6李敏清,黄星,陈军.VCAM-1和TNF-α在重度子痫前期合并胎儿生长受限患者母血及脐血中的表达[J].广西医科大学学报,2012,29(6):857-859. 被引量:8
  • 7马学芹,于世鹏.初发Graves病患者^(131)I治疗前后IL-23/Th17轴相关因子水平的变化及意义[J].中国免疫学杂志,2013,29(7):733-735. 被引量:10
  • 8刘少正,张青.Graves甲亢131I治疗后甲状腺功能减退的因子分析[J].江西医药,2013,48(1):85-89. 被引量:3

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部